Reader Comments
Post a new comment on this article
Post Your Discussion Comment
Please follow our guidelines for comments and review our competing interests policy. Comments that do not conform to our guidelines will be promptly removed and the user account disabled. The following must be avoided:
- Remarks that could be interpreted as allegations of misconduct
- Unsupported assertions or statements
- Inflammatory or insulting language
Thank You!
Thank you for taking the time to flag this posting; we review flagged postings on a regular basis.
closeAppendix
Posted by katsunori on 02 Dec 2013 at 07:54 GMT
The main funding sources for the genetic study of this article were 1. the Japanese Ministry of Education, Culture, Sports, Science and Technology Grant-in-Aid for Scientific Research, 2. the Japanese Ministry of Health, Labour and Welfare and 3. the Japan Science and Technology Agency.
DNA samples were collected from IORRA cohort study which is supported in part by most major pharmaceutical companies in Japan (up to 40) since 2000. Japan Tobacco Inc. is one of the pharmaceutical companies that manufactures and distributes pharmaceuticals. Grants from these pharmaceutical companies were unrestricted research grants and were used only to maintain the cohort study. The grant funders of IORRA cohort study have no role in the study design; in the collection, analysis and/or interpretation of the data; in the writing of the report; and in the decision to submit the paper for publication. Japan Tobacco Inc. was involved in the funding for the IORRA cohort study but this company did not provide funding for the genetic study reported in the current article.